日本Ono Pharmaceutical  www.ono.co.jp 
日本小野制藥株式會(huì)社(ono pharmaceutical)

Ono Pharmaceutical Co., Ltd. is an R&D-oriented pharmaceutical company specialized in creating innovative medicines for the treatment of various indications with unmet medical need at the frontline of healthcare. The Company focuses on drug discovery leads that are high in certainty and globally-competitive, promoting alliances with biopharmaceutical companies in the US and Europe as well as research collaborations with universities and other research institutions. Ono’s drug discovery efforts focus on the therapeutic application of bioactive lipids and enzyme inhibitors in the areas of inflammation, autoimmune disease, cancer, cardiovascular diseases and CNS disorders. The Company’s strategic partnerships are not solely directed towards the discovery of new drug candidates, but also include international in-licensing agreements (e.g. Merck & Co. Inc. in the USA) to strengthen Ono’s ever-expanding development pipeline. Ono already manufactures and markets a broad portfolio of prescription pharmaceuticals targeting a wide range of indications such as Alzheimer’s disease, type II diabetes, osteoporosis, chemotherapy-induced nausea and bronchial asthma. Ono is a firmly established pharmaceutical company, headquartered in Osaka, Japan and listed on the Tokyo Stock Exchange since 1963.